|
| |
XCYTE THERAPIES anti-CD3 Pages on BioPortfolio:
Results from other life science and pharmaceutical sites:
BioPortfolio - Xcyte Therapies Incorporated
4 Nov 2008 ... Xcyte Therapies Incorporated - Entry on Bioportfolio's Biocorporate Database. ... beads conjugated with anti-CD3 and Anti-CD28 antibodies. ...
http://www.bioportfolio.com/biocorporate/11082-Xcyte_Therapi...
|
Optimization of human T-cell expansion ex vivo using magnetic ...
Xcyte Therapies, Inc., Seattle, Washington 98104, USA. ... are activated and expanded in culture ex vivo using anti-CD3 and anti-CD28 monoclonal antibodies
...
http://www.ncbi.nlm.nih.gov/pubmed/15314550...
|
BioPortfolio - xcyte therapeutics,
1 Mar 2008 ... BioPortfolio - xcyte therapeutics, Xcyte Therapies Inc announces withdrawal of ... FACS®-purified T cells were stimulated with anti-CD3 and ...
http://www.bioportfolio.com/search/xcyte_therapeutics,.html...
|
Molecular Therapy - Abstract of article: 709. Comparison of the ...
|[ast]|MLB is an employee of Xcyte Therapies, Inc., and has equity (stock) ... after activation with anti-CD3/anti-CD28 coated beads and gene-modified cells
...
http://www.nature.com/mt/journal/v11/n1s/abs/mt2005829a.html...
|
Expression and characterization of recombinant sol...[Int Immunol ...
Xcyte Therapies, Inc., Seattle, WA 98104, USA. ... The sc CD3deltaepsilon-scIg reacted with anti-CD3 mAb without requiring acid treatment. ...
http://www.ncbi.nlm.nih.gov/pubmed/11934875...
|
Molecular Therapy - Transfer of Autologous Gene-modified T Cells ...
108 CD3+ cells were then incubated with anti-CD3/anti-CD28-coated Xcyte Dynabeads (Xcyte Therapies, Seattle, WA) at a CD3+ cell to bead ratio of 1:3 for
30 ...
http://www.nature.com/mt/journal/v15/n5/full/6300124a.html...
|
In Vitro–expanded Antigen-specific Regulatory T Cells Suppress ...
3Xcyte Therapies, Inc., Seattle, WA 98104 .... When indicated, expanded Tregs were depleted of anti-CD3 and anti-CD28 beads and washed extensively before ...
http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=22...
|
Gene Therapy - Preferential retroviral-mediated transduction of ...
When T cells were alternatively activated by CD3/CD28 beads (Xcyte Therapies Inc ., Seattle, WA, USA)+IL-2 (CD3/CD28/IL-2), transduction efficiencies of bulk ...
http://www.nature.com/gt/journal/v11/n12/full/3302273a.html...
|
Standardized analysis for the quantification of Vbeta CDR3 T-cell ...
Xcyte Therapies, Inc., Seattle, WA, USA. along@benaroyaresearch.org ... Upon in vitro activation with anti-CD3 and anti-CD28 coated beads (Xcyte Dynabeads) ...
http://www.ncbi.nlm.nih.gov/pubmed/17081557...
|
GrpL, a Grb2-related Adaptor Protein, Interacts with SLP-76 to ...
Overexpression of GrpL alone consistently augmented anti-CD3– induced NF-AT ..... C.-L. Law's present address is Xcyte Therapies Inc., 2203 Airport Way ...
http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=21...
|
|
